Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type and type 2 cytokine production

Details for Australian Patent Application No. 2006331950 (hide)

Owner Abbott Laboratories

Inventors Thomas, Debra L.; Mukerji, Pradip

Agent Spruson & Ferguson

Pub. Number AU-A-2006331950

PCT Pub. Number WO2007/075605

Priority 60/752,253 19.12.05 US

Filing date 19 December 2006

Wipo publication date 5 July 2007

International Classifications

A61K 31/19 (2006.01)

A61P 31/00 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 35/00 (2006.01) Antineoplastic agents

A61P 37/08 (2006.01) Drugs for immunological or allergic disorders

Event Publications

26 June 2008 PCT application entered the National Phase

  PCT publication WO2007/075605 Priority application(s): WO2007/075605

10 July 2008 Amendment Made

  The nature of the amendment is: Amend the invention title to read: Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance of type 1 and type 2 cytokine production

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006331963-Substituted piperidines as calcium channel blockers

2006331947-Methods for assessing the proinflammatory immune health of an individual